Humana (HUM) Earnings Date & Reports

Key Takeaways

• Humana is scheduled to report third quarter 2026 (3Q26) results on Friday, November 6, 2026, before the market opens.
• Wall Street consensus points to a quarterly loss of roughly $1.00 per share, compared with a $3.24 profit in the year-ago period.
• Consensus revenue of about $40.87 billion implies growth of roughly 25% from $32.65 billion a year earlier.
• Investors are focused on the medical loss ratio (the share of premiums spent on medical care), Medicare Advantage margins, and membership trends.
• Humana has beaten consensus EPS in seven of its last eight quarters, a track record that raises the bar for this report.

Earnings Context and Why It Matters

Humana is one of the largest Medicare-focused health insurers in the United States, so its quarterly results offer a broad read on the profitability of Medicare Advantage (privately run Medicare plans) and the cost of medical care for older Americans. The company has delivered strong top-line growth in 2026, with revenue up 26.2% year over year in the second quarter, but rising benefit costs have pressured margins. Management has repeatedly pointed to a gap between government reimbursement rates and medical cost trends as a key headwind. This report will show whether Humana's pricing, benefit design, and cost-management efforts are translating into a more sustainable margin recovery, making it a closely watched update for both shareholders and the broader managed-care sector.

Earnings Expectations

Analysts expect Humana to report a third-quarter loss of approximately $1.00 per share, according to consensus data. That compares with earnings of $3.24 per share in the third quarter of 2025 and reflects the seasonal and cost-related pressures the company has flagged throughout the year. The range of analyst estimates is wide, spanning roughly a $0.60 loss to a $1.16 loss per share, underscoring meaningful uncertainty around medical cost trends. On the top line, consensus revenue is about $40.87 billion, up roughly 25.2% from $32.65 billion a year earlier.

For context, Humana reported adjusted earnings of $7.61 per share in the second quarter of 2026, beating consensus, and $10.31 per share in the first quarter. The company also affirmed its full-year 2026 adjusted earnings guidance in its last update. Key metrics to watch include the consolidated benefit ratio (medical costs as a percentage of premium revenue), which stood at 91.1% in the second quarter, and total medical membership, which reached 17.9 million in the insurance segment at the end of the second quarter.

AI Screener

Investors tracking earnings season can streamline their research with Tickeron's AI Screener, an AI-powered stock and ETF discovery tool designed to filter the market by technical patterns, fundamentals, trends, volatility, and AI-driven signals. The screener lets users scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For those following managed-care names like Humana, it can help surface breakout candidates, trending stocks, and new trade ideas far more efficiently than manual screening. Explore the AI Screener to uncover opportunities aligned with your strategy.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious but attentive. Humana shares have experienced notable swings in recent weeks, including a sharp single-session gain of more than 11% in October, reflecting investor sensitivity to Medicare Advantage policy and reimbursement developments. At the same time, consensus earnings estimates for the quarter have drifted lower over the past month, which can signal moderating near-term expectations. The stock's history of beating estimates — seven of the last eight quarters — means investors may look beyond the headline loss and focus on the benefit ratio, margin trajectory, and any updated commentary on 2027 pricing. A larger-than-expected loss, a deteriorating medical cost ratio, or disappointing membership figures would likely weigh on the shares, while signs of margin stabilization could support sentiment.

Forward Outlook and Key Factors to Monitor

Beyond the headline figures, investors will be listening for signals on Humana's path back to a sustainable Medicare Advantage margin. Management has laid out a multi-year goal of returning the individual Medicare Advantage business to a margin of at least 3% by 2028, and commentary on progress toward that target will be closely scrutinized.

Several factors will shape the outlook. First, the benefit ratio and medical cost trend remain the central question, since any indication that costs are running above reimbursement levels would pressure near-term profitability. Second, membership growth and retention across Medicare Advantage and the CenterWell primary care and pharmacy segment will help gauge whether Humana is balancing growth with pricing discipline.

Finally, regulatory and reimbursement developments remain key catalysts. Updates on government funding rates, Medicare Star Ratings, and benefit design decisions for 2027 could meaningfully influence earnings power next year. While near-term results are expected to reflect seasonal pressure, investors will be watching whether the company's cost-management initiatives and strategic pricing set the stage for improvement in 2027 and beyond.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations